As the ECCO position paper on access to innovation
makes clear, the necessary starting point to the measurement of value of any innovation is to determine whether it offers real benefits to patients. This requires a comprehensive assessment of its impact on patient outcomes, quality of life, quality of care and costs across the system.
Various approaches have been initiated towards the goal of establishing a transportable understanding of value in healthcare. But what are the optimal approaches, and could it be possible to apply a harmonised approach across different domains (e.g. pharmaceutical and non-systemic treatments)?
It is with these questions in mind that ECCO has launched a project examining value-based healthcare’s application across the cancer care spectrum.
Led by Professor Yolande Lievens (President, ESTRO), phase 1 of the project brings together a core group of experts to identify and reflect on existing methodologies for assessing value, and after critical evaluation, produce initial reflections and recommendations about the additions/adjustments needed for application in non-systemic oncology treatment.
The members of the expert core group are:
- Yolande Lievens, (Project Chair), President of ESTRO
- Riccardo Audisio, Past-President of ESSO
- Elizabeth De Vries, Co-Chair of the ESMO-MCBS Task Force
- Cai Grau, Chair of the HERO project
- Ajay Agarwal, Clinical Oncologist and visiting Senior Research Fellow at the Institute of Cancer Policy (King's College London)
- Laurence Collette, Head of Statistics Department, EORTC
- Kathy Oliver, Co-Director, International Brain Tumour Alliance (IBTA)
In the second phase of the project, input and scrutiny will be invited from a wider range of stakeholders in order to refine propositions. Individuals interested in involvement in this second phase of the project are invited to contact firstname.lastname@example.org.
Further news about the progress of the project will be shared on this page and via the ECCO newsletter.
PRINT THIS PAGE
Page last modified: